ACS chemical neuroscience molecule spotlight on savella.

ABSTRACT: Savella (milnacipran), a selective serotonin and noradrenaline reuptake inhibitor, was approved by the FDA on January 14th, 2009, for the treatment of fibromyalgia.

SUBMITTER: Hopkins CR 

PROVIDER: S-EPMC3368674 | biostudies-other | 2010 May

REPOSITORIES: biostudies-other